Citations (88)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (27)
Guohua Lin, Jiaqi Zheng, Pou Kuan Tang, Yu Zheng, Hao Hu & Carolina Oi Lam Ung. (2022) Effectiveness of Hospital Pharmacist Interventions for COPD Patients: A Systematic Literature Review and Logic Model. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2757-2788.
Read now
Read now
Yi-Han Hsiao, Ching-Min Tseng, Chau-Chyun Sheu, Hsin-Yi Wang, Hsin-Kuo Ko, Kang-Cheng Su, Chi-Wei Tao, Ming-Ju Tsai & Yen-Fu Chen. (2022) Shared Decision-Making Facilitates Inhaler Choice in Patients with Newly-Diagnosed Chronic Obstructive Pulmonary Disease: A Multicenter Prospective Study. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2067-2078.
Read now
Read now
Harjit Dumra, Arjun Khanna, Sujeet K Madhukar, Meena Lopez & Jaideep Gogtay. (2022) Perceptions and Attitudes of Patients and Their Family Caregivers on Nebulization Therapy for COPD. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2277-2288.
Read now
Read now
Anne Tschacher, Cordula Cadus, Sebastian Schildge, Jens Peter Diedrich, Prashant N. Chhajed, Anne B. Leuppi-Taegtmeyer & Jörg Daniel Leuppi. (2021) Switching COPD patients from the disposable to the new reusable Respimat soft mist inhaler: a real-world study from Switzerland. Current Medical Research and Opinion 37:11, pages 2019-2033.
Read now
Read now
Judith J Stephenson, Carole Dembek, Amanda Caldwell-Tarr, Rebecca M Conto, Mark Paullin & Edward M Kerwin. (2020) Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 1713-1727.
Read now
Read now
Omar S Usmani. (2019) Choosing the right inhaler for your asthma or COPD patient. Therapeutics and Clinical Risk Management 15, pages 461-472.
Read now
Read now
Rajiv Dhand, Joachim Eicher, Michaela Hänsel, Ingeborg Jost, Martin Meisenheimer & Herbert Wachtel. (2019) Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. International Journal of Chronic Obstructive Pulmonary Disease 14, pages 509-523.
Read now
Read now
Andrea S. Melani. (2018) Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy 19:14, pages 1603-1611.
Read now
Read now
Gary T. Ferguson & Richard N. Dalby. (2018) Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease. Postgraduate Medicine 130:6, pages 515-522.
Read now
Read now
Kwun Nok Mimi Man, Zhipeng Tian, David Chi-Leung Lam, Jennifer Man Fan Wan & Kian Cheng Tan-Un. (2018) Satisfaction, preference and error occurrence of three dry powder inhalers as assessed by a cohort naïve to inhaler operation. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1949-1963.
Read now
Read now
Kathryn A Collison, Pinal Patel, Andrew F Preece, Richard H Stanford, Raj K Sharma & Gregory Feldman. (2018) A Randomized Clinical Trial Comparing the ELLIPTA and HandiHaler Dry Powder Inhalers in Patients With COPD: Inhaler-Specific Attributes and Overall Patient Preference. COPD: Journal of Chronic Obstructive Pulmonary Disease 15:1, pages 46-50.
Read now
Read now
Francisco García-Río, Juan J Soler-Cataluña, Bernardino Alcazar, José L Viejo & Marc Miravitlles. (2017) Requirements, Strengths and Weaknesses of Inhaler Devices for COPD Patients from the Expert Prescribers' Point of View: Results of the EPOCA Delphi Consensus. COPD: Journal of Chronic Obstructive Pulmonary Disease 14:6, pages 573-580.
Read now
Read now
Mette Bøgelund, Lise Hagelund & Mikael Bergholdt Asmussen. (2017) COPD-treating nurses’ preferences for inhaler attributes – a discrete choice experiment. Current Medical Research and Opinion 33:1, pages 71-75.
Read now
Read now
Pieter Nicolaas Richard Dekhuijzen, Federico Lavorini & Omar S Usmani. (2016) Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat® or HandiHaler®. Patient Preference and Adherence 10, pages 1561-1572.
Read now
Read now
Christina Kunz, Doreen Luedtke, Anna Unseld, Alan Hamilton, Atef Halabi, Martina Wein & Stephan Formella. (2016) Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 585-595.
Read now
Read now
Pinar Yildiz, Mesut Bayraktaroglu, Didem Gorgun & Funda Secik. (2016) Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 2859-2867.
Read now
Read now
John H Riley, Maggie Tabberer, Nathalie Richard, Alison Donald, Alison Church & Stephanie S Harris. (2016) Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 1873-1880.
Read now
Read now
Suyong Yun Kirby, Chang-Qing Zhu, Edward M. Kerwin, Richard H. Stanford & George Georges. (2016) A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA® Dry Powder Inhaler (DPI) versus DISKUS® DPI. COPD: Journal of Chronic Obstructive Pulmonary Disease 13:2, pages 167-175.
Read now
Read now
Soichiro Hanada, Shota Wada, Takeshi Ohno, Hirochiyo Sawaguchi, Masato Muraki & Yuji Tohda. (2015) Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 69-77.
Read now
Read now
Andrea Rossi, Erika Zanardi, Venerino Poletti & Mario Cazzola. (2015) Clinical role of dual bronchodilation with an indacaterol–glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1383-1392.
Read now
Read now
Andrew R Martin & Warren H Finlay. (2015) Nebulizers for drug delivery to the lungs. Expert Opinion on Drug Delivery 12:6, pages 889-900.
Read now
Read now
Job van der Palen, Paul van der Valk, Martijn Goosens, Karin Groothuis-Oudshoorn & Marjolein Brusse-Keizer. (2013) A randomised cross-over trial investigating the ease of use and preference of two dry powder inhalers in patients with asthma or chronic obstructive pulmonary disease. Expert Opinion on Drug Delivery 10:9, pages 1171-1178.
Read now
Read now
Amir Sharafkhaneh, Ray A. Wolf, Sheila Goodnight, Nicola A. Hanania, Barry J. Make & Donald P. Tashkin. (2013) Perceptions and Attitudes Toward the Use of Nebulized Therapy for COPD: Patient and Caregiver Perspectives. COPD: Journal of Chronic Obstructive Pulmonary Disease 10:4, pages 482-492.
Read now
Read now
Job van der Palen, Thomas Ginko, Axel Kroker, Paul van der Valk, Martijn Goosens, Laura Padullés, Beatriz Seoane, Ludmyla Rekeda & Esther Garcia Gil. (2013) Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opinion on Drug Delivery 10:8, pages 1023-1031.
Read now
Read now
Ralph J Panos. (2013) Efficacy and safety of eco-friendly inhalers: focus on combination ipratropium bromide and albuterol in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 8, pages 221-230.
Read now
Read now
Rajiv Dhand, Myrna Dolovich, Bradley Chipps, Timothy R. Myers, Ruben Restrepo & Judith Rosen Farrar. (2012) The Role of Nebulized Therapy in the Management of COPD: Evidence and Recommendations. COPD: Journal of Chronic Obstructive Pulmonary Disease 9:1, pages 58-72.
Read now
Read now
Felix SF Ram, Celso R Carvallho & John White. (2011) Clinical effectiveness of the Respimat® inhaler device in managing chronic obstructive pulmonary disease: evidence when compared with other handheld inhaler devices. International Journal of Chronic Obstructive Pulmonary Disease 6, pages 129-139.
Read now
Read now
Articles from other publishers (61)
Hao Miao, Ke Huang, Yingwen Li, Renjie Li, Xudong Zhou, Jingyu Shi, Zhenbo Tong, Zhenhua Sun & Aibing Yu. (2023) Optimization of formulation and atomization of lipid nanoparticles for the inhalation of mRNA. International Journal of Pharmaceutics 640, pages 123050.
Crossref
Crossref
Jiankang Wu, Yiming Ma & Yan Chen. (2023) Extracellular vesicles and COPD: foe or friend?. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Mary Manoranjani ADDANKİ, Prakash KATAKAM, Shanta Kumari ADIKI, Jessi Dason VARDHANAPU, Nagabhushana Vinay Kumar ALA, Surekha ITAMREDDY, Sudhakar MUVVALA & Parthiban CHINNACHAMY. (2023) FORMULATION AND IN VITRO - IN VIVO EVALUATION OF TETANUS TOXOID-MANNITOL DRY POWDER INHALATION FOR PULMONARY DELIVERY. Ankara Universitesi Eczacilik Fakultesi Dergisi.
Crossref
Crossref
M. Matuszak, M. Ochowiak, S. Włodarczak, A. Krupińska & M. Doligalski. (2022) State-of-the-art review of the application and development of various methods of aerosol therapy. International Journal of Pharmaceutics 614, pages 121432.
Crossref
Crossref
Epaminondas Kosmas, Iraklis Titopoulos, Georgios Patentalakis & Nikos Nikas. (2021) An Observational Study Assessing Changes in Health and Functional Status in Patients with Chronic Obstructive Pulmonary Disease (COPD) During Therapy with Spiolto® Respimat® in Everyday Clinical Practice: The Greek ELLACTO Study. Pulmonary Therapy 7:2, pages 429-443.
Crossref
Crossref
Yingmin Liang & Judith C.W. Mak. (2021) Inhaled Therapies for Asthma and Chronic Obstructive Pulmonary Disease. Current Pharmaceutical Design 27:12, pages 1469-1481.
Crossref
Crossref
Sarah E. Petite, Michael W. Hess & Herbert Wachtel. (2020) The Role of the Pharmacist in Inhaler Selection and Education in Chronic Obstructive Pulmonary Disease. Journal of Pharmacy Technology 37:2, pages 95-106.
Crossref
Crossref
Michael Dreher, David Price, Asparuh Gardev, Pascale Peeters, Satish Arora, Simone van der Sar – van der Brugge, Richard Dekhuijzen & Omar S Usmani. (2021)
Patient perceptions of the re-usable Respimat
®
Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
. Chronic Respiratory Disease 18, pages 147997312098622.
Crossref
Crossref
Mauro Carone, Alfio Pennisi, Mariella D’Amato, Alfeo Fiore Donati, Alberto Ricci, Carla Scognamillo, Li Chun, Maria Aliani, Valeria Ronsivalle & Girolamo Pelaia. (2020) Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy. Pulmonary Therapy 6:2, pages 261-274.
Crossref
Crossref
Tamas ErdelyiZsofia LazarBalazs OdlerLilla TamasiVeronika Müller. (2020) The Repeatability of Inspiration Performance Through Different Inhalers in Patients with Chronic Obstructive Pulmonary Disease and Control Volunteers. Journal of Aerosol Medicine and Pulmonary Drug Delivery 33:5, pages 271-281.
Crossref
Crossref
Timothy R Hudd. (2020) Emerging role of pharmacists in managing patients with chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy 77:19, pages 1625-1630.
Crossref
Crossref
Massimiliano Povero, Paola Turco, Luca Bonadiman & Roberto W. Dal Negro. (2020) The Global Usability Score Short-Form for the simplified assessment of dry powder inhalers (DPIs) usability. Multidisciplinary Respiratory Medicine 15.
Crossref
Crossref
Gustaf Ortsäter, Fredrik Borgström, Mike Baldwin & Carolin Miltenburger. (2019) Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler. Applied Health Economics and Health Policy 18:3, pages 433-442.
Crossref
Crossref
Suzanne G Bollmeier & Aaron P Hartmann. (2020) Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. American Journal of Health-System Pharmacy 77:4, pages 259-268.
Crossref
Crossref
Maryam Navaie, Carole Dembek, Soojin Cho-Reyes, Karen Yeh & Bartolome R. Celli. (2020) Inhaler device feature preferences among patients with obstructive lung diseases. Medicine 99:25, pages e20718.
Crossref
Crossref
Haley Hoy & Louise O'Keefe. (2020) Choosing the right inhaler for the right patient: Considerations for effective management of patients with chronic obstructive pulmonary disease or asthma. Journal of the American Association of Nurse Practitioners 32:1, pages 89-99.
Crossref
Crossref
Santhalingam Balamurugan, Komalkirti Apte, Bhanu Pratap Singh, Ashish Kumar Deb, Chandrahas Deshmukh, Kinjal Modi, Ajay Godse, Raja Dhar, Keya Rani Lahiri, Virendra Singh, Hiren Pandya, Sujeet Rajan, Abhijit Vaidya, Vaibhav Gaur & Jaideep Gogtay. (2020) Device-handling study of a novel breath-actuated inhaler, Synchrobreathe®, versus a pMDI. Respiratory Medicine 161, pages 105707.
Crossref
Crossref
Roberto W. Dal Negro, Paola Turco & Massimiliano Povero. (2019) Patients’ usability of seven most used dry-powder inhalers in COPD. Multidisciplinary Respiratory Medicine 14:1.
Crossref
Crossref
Gustaf Ortsäter, Fredrik Borgström, Stéphane Soulard & Carolin Miltenburger. (2019) A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT® Re-usable in the Nordics and Benelux. Advances in Therapy 36:12, pages 3435-3445.
Crossref
Crossref
Takashi Iwanaga, Yuji Tohda, Shuhei Nakamura & Yasunori Suga. (2019) The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients. Clinical Drug Investigation 39:11, pages 1021-1030.
Crossref
Crossref
Anthony D’Urzo, Kenneth R. Chapman, James F. Donohue, Peter Kardos, M. Reza Maleki-Yazdi & David Price. (2019) Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD. Pulmonary Therapy 5:1, pages 23-41.
Crossref
Crossref
Edward M. KerwinJames F. DonohueGary T. FergusonVaidyanathan GanapathyAyca Ozol-GodfreyKrithika Rajagopalan. (2019) Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery 32:1, pages 24-33.
Crossref
Crossref
José Eduardo Delfini Cançado, Rodrigo Abensur Athanazio, Luis Fernando Rensi Cunha & Marcia Margaret Menezes Pizzichini. (2019) Prescribing trends in and perceptions of the treatment of asthma: a survey among pulmonologists in Brazil. Jornal Brasileiro de Pneumologia 45:5.
Crossref
Crossref
Claudia Gregoriano, Thomas Dieterle, Anna-Lisa Breitenstein, Selina Dürr, Amanda Baum, Sabrina Maier, Isabelle Arnet, Kurt E. Hersberger & Jörg D. Leuppi. (2018) Use and inhalation technique of inhaled medication in patients with asthma and COPD: data from a randomized controlled trial. RESPIRATORY RESEARCH 19:1.
Crossref
Crossref
Maria Vera Cruz de Oliveira, Emilio Pizzichini, Claudia Henrique da Costa, Carlos Cezar Fritscher, Elcio Oliveira Vianna, Paulo José Zimermann Teixeira, Roberto Stirbulov, Marcelo Fouad Rabahi & Nadine Cordeiro de Pinho. (2018) Evaluation of the preference, satisfaction and correct use of Breezhaler® and Respimat® inhalers in patients with chronic obstructive pulmonary disease – INHALATOR study. Respiratory Medicine 144, pages 61-67.
Crossref
Crossref
Herbert Wachtel, Mark Nagel, Michael Engel, Georges El Azzi, Ashish Sharma & Jason Suggett. (2018) In vitro and clinical characterization of the valved holding chamber AeroChamber Plus ® Flow-Vu ® for administrating tiotropium Respimat ® in 1–5-year-old children with persistent asthmatic symptoms. Respiratory Medicine 137, pages 181-190.
Crossref
Crossref
Magdalena Matuszak, Marek Ochowiak & Michał Doligalski. 2018. Practical Aspects of Chemical Engineering. Practical Aspects of Chemical Engineering
275
289
.
Kimberly H. Davis, Jun Su, Juan Marcos González, Jeremiah J. Trudeau, Lauren M. Nelson, Brett Hauber & Kelly A. Hollis. (2017) Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. Health and Quality of Life Outcomes 15:1.
Crossref
Crossref
Natalia Hawken, Saku Torvinen, Mohamed-Elmoctar Neine, Ikbel Amri, Mondher Toumi, Samuel Aballéa, Adam Plich & Nicolas Roche. (2017) Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment. BMC Pulmonary Medicine 17:1.
Crossref
Crossref
Henrik Svedsater, David Leather, Terry Robinson, Helen Doll, Beenish Nafees & Lisa Bradshaw. (2017) Evaluation and quantification of treatment preferences for patients with asthma or COPD using discrete choice experiment surveys. Respiratory Medicine 132, pages 76-83.
Crossref
Crossref
Joachim H. Ficker, Klaus F. Rabe & Tobias Welte. (2017) Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology & Therapeutics 45, pages 19-33.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Herbert Wachtel, Sabine Kattenbeck, Stephen Dunne & Bernd Disse. (2017) The Respimat® Development Story: Patient-Centered Innovation. Pulmonary Therapy 3:1, pages 19-30.
Crossref
Crossref
Paola Rogliani, Luigino Calzetta, Angelo Coppola, Francesco Cavalli, Josuel Ora, Ermanno Puxeddu, Maria Gabriella Matera & Mario Cazzola. (2017) Optimizing drug delivery in COPD: The role of inhaler devices. Respiratory Medicine 124, pages 6-14.
Crossref
Crossref
Thaigarajan Parumasivam, Sharon S. Y. Leung, Patricia Tang, Citterio Mauro, Warwick Britton & Hak-Kim Chan. (2016) The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. The AAPS Journal 19:1, pages 191-202.
Crossref
Crossref
Thys van der Molen, Job F. M. van Boven, Terence Maguire, Pankaj Goyal & Pablo Altman. (2017) Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist. British Journal of Clinical Pharmacology 83:1, pages 192-201.
Crossref
Crossref
Roberto W. Dal Negro & Massimiliano Povero. (2016) Acceptability and preference of three inhalation devices assessed by the Handling Questionnaire in asthma and COPD patients. Multidisciplinary Respiratory Medicine 11:1.
Crossref
Crossref
Ronald Dahl & Alan Kaplan. (2016) A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?. BMC Pulmonary Medicine 16:1.
Crossref
Crossref
Job van der Palen, Mike Thomas, Henry Chrystyn, Raj K Sharma, Paul DLPM van der Valk, Martijn Goosens, Tom Wilkinson, Carol Stonham, Anoop J Chauhan, Varsha Imber, Chang-Qing Zhu, Henrik Svedsater & Neil C Barnes. (2016) A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. npj Primary Care Respiratory Medicine 26:1.
Crossref
Crossref
Thaigarajan Parumasivam, Rachel Yoon Kyung Chang, Sharif Abdelghany, Tian Tian Ye, Warwick John Britton & Hak-Kim Chan. (2016) Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews 102, pages 83-101.
Crossref
Crossref
Deborah BickmannWolfgang KaminAshish SharmaHerbert WachtelPetra Moroni-ZentgrafStefan Zielen. (2016)
In Vitro
Determination of Respimat
®
Dose Delivery in Children: An Evaluation Based on Inhalation Flow Profiles and Mouth–Throat Models
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 29:1, pages 76-85.
Crossref
Crossref
Matteo Bonini & Omar S. Usmani. (2015) The importance of inhaler devices in the treatment of COPD. COPD Research and Practice 1:1.
Crossref
Crossref
Guido Ern. (2015) Inhalator-Wahl, Schulung und Kontrolle: Praxisrealität der COPD-Therapie bei Hausärzten und FachangestelltenGermany-wide outpatient healthcare research. Inhaler choice, training and monitoring: reality of COPD therapy of GPs and medical assistants. MMW - Fortschritte der Medizin 157:S7, pages 1-7.
Crossref
Crossref
Deborah Duncan. (2015) Medication adherence in chronic obstructive pulmonary disease. Practice Nursing 26:10, pages 493-498.
Crossref
Crossref
Wolfgang KaminMarion FrankSabine KattenbeckPetra Moroni-ZentgrafHerbert WachtelStefan Zielen. (2015)
A Handling Study to Assess Use of the Respimat
®
Soft Mist™ Inhaler in Children Under 5 Years Old
. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:5, pages 372-381.
Crossref
Crossref
Mathieu MolimardPaul Colthorpe. (2015) Inhaler Devices for Chronic Obstructive Pulmonary Disease: Insights from Patients and Healthcare Practitioners. Journal of Aerosol Medicine and Pulmonary Drug Delivery 28:3, pages 219-228.
Crossref
Crossref
F. Trotta, R. Da Cas, M. Rajevic, M. Rossi & G. Traversa. (2015) Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study. BMJ Open 5:5, pages e006619-e006619.
Crossref
Crossref
Sergi Pascual, Jan Feimer, Anthony De Soyza, Jaume Sauleda Roig, John Haughney, Laura Padullés, Beatriz Seoane, Ludmyla Rekeda, Anna Ribera & Henry Chrystyn. (2015) Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in patients with COPD: a randomised, cross-over, multicentre study. npj Primary Care Respiratory Medicine 25:1.
Crossref
Crossref
Deborah Duncan. (2015) Medication adherence in chronic obstructive pulmonary disease. Nurse Prescribing 13:4, pages 172-177.
Crossref
Crossref
. (2015) ▼Olodaterol—another LABA for COPD. Drug and Therapeutics Bulletin 53:4, pages 42-45.
Crossref
Crossref
John Gar Yan Chan, Jennifer Wong, Qi Tony Zhou, Sharon Shui Yee Leung & Hak-Kim Chan. (2014) Advances in Device and Formulation Technologies for Pulmonary Drug Delivery. AAPS PharmSciTech 15:4, pages 882-897.
Crossref
Crossref
J.M. Hohlfeld, A. Sharma, J.A. van Noord, P.J.G. Cornelissen, E. Derom, L. Towse, V. Peterkin & B. Disse. (2013) Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. The Journal of Clinical Pharmacology 54:4, pages 405-414.
Crossref
Crossref
Henry Chrystyn, Mark Small, Gary Milligan, Victoria Higgins, Esther Garcia Gil & Jordi Estruch. (2014) Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respiratory Medicine 108:2, pages 358-365.
Crossref
Crossref
Henrik Svedsater, Peter Dale, Karl Garrill, Richard Walker & Mark W Woepse. (2013) Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulmonary Medicine 13:1.
Crossref
Crossref
Katie Campoli Meyer. (2013) COPD 2013: An update on treatment and newly approved medications for pharmacists. Journal of the American Pharmacists Association 53:6, pages e219-e231.
Crossref
Crossref
Katie Campoli Meyer. (2013) COPD 2013: An update on treatment and newly approved medications for pharmacists. Pharmacy Today 19:11, pages 53-64.
Crossref
Crossref
Roger Abrahams, Petra Moroni-Zentgraf, Joe Ramsdell, Hendrik Schmidt, Elizabeth Joseph & Jill Karpel. (2013) Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Respiratory Medicine 107:6, pages 854-862.
Crossref
Crossref
J.A. van Noord, J.J. Smeets, B.M. Drenth, J. Rascher, A. Pivovarova, A.L. Hamilton & P.J.G. Cornelissen. (2011) 24-hour Bronchodilation following a single dose of the novel β2-agonist olodaterol in COPD. Pulmonary Pharmacology & Therapeutics 24:6, pages 666-672.
Crossref
Crossref
L Lo Valvo, S Leonardi, Gl Marseglia, Miraglia M Del Giudice, C Salpietro, G Ciprandi & M La Rosa. (2011) Inhalation Therapy in Asthmatic and Not Asthmatic Children. International Journal of Immunopathology and Pharmacology 24:4_suppl, pages 61-67.
Crossref
Crossref
A.-C. Henriet, S. Marchand-Adam, J. Mankikian & P. Diot. (2010) Respimat®, premier inhalateur « Soft Mist » : intérêt dans la prise en charge de la BPCO. Revue des Maladies Respiratoires 27:10, pages 1141-1149.
Crossref
Crossref
E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, D. Pavia & N.S. Zhong. (2010) A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respiratory Medicine 104:10, pages 1460-1472.
Crossref
Crossref